Globus Medical, Inc. (NYSE:GMED) has been assigned a consensus rating of “Hold” from the fifteen brokerages that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $31.20.

A number of equities analysts have recently issued reports on GMED shares. BidaskClub downgraded shares of Globus Medical from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 26th. Barclays PLC dropped their price objective on shares of Globus Medical from $28.00 to $27.00 and set an “underweight” rating on the stock in a research note on Thursday, October 19th. Zacks Investment Research downgraded shares of Globus Medical from a “hold” rating to a “sell” rating in a research note on Monday, September 4th. Piper Jaffray Companies reiterated a “buy” rating on shares of Globus Medical in a research note on Thursday, October 19th. Finally, Needham & Company LLC started coverage on shares of Globus Medical in a research note on Tuesday, September 26th. They set a “hold” rating on the stock.

ILLEGAL ACTIVITY NOTICE: This piece was published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.americanbankingnews.com/2017/11/05/globus-medical-inc-gmed-given-average-rating-of-hold-by-brokerages.html.

Globus Medical (NYSE:GMED) opened at $31.36 on Friday. Globus Medical has a one year low of $19.25 and a one year high of $34.03. The stock has a market cap of $3,019.69, a P/E ratio of 25.29, a PEG ratio of 2.37 and a beta of 0.55.

Globus Medical (NYSE:GMED) last released its quarterly earnings data on Wednesday, August 2nd. The medical device company reported $0.32 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.30 by $0.02. Globus Medical had a net margin of 18.12% and a return on equity of 13.99%. The firm had revenue of $152.39 million for the quarter, compared to the consensus estimate of $150.94 million. During the same period last year, the firm earned $0.29 earnings per share. The company’s quarterly revenue was up 10.8% on a year-over-year basis. equities analysts expect that Globus Medical will post 1.27 EPS for the current fiscal year.

In other Globus Medical news, insider A Brett Murphy sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $29.99, for a total value of $449,850.00. Following the completion of the sale, the insider now directly owns 101,217 shares in the company, valued at $3,035,497.83. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 28.21% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in shares of Globus Medical by 0.3% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 10,538 shares of the medical device company’s stock worth $349,000 after buying an additional 31 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Globus Medical by 1.2% in the second quarter. PNC Financial Services Group Inc. now owns 3,036 shares of the medical device company’s stock worth $100,000 after buying an additional 35 shares during the last quarter. Alps Advisors Inc. raised its holdings in shares of Globus Medical by 0.3% in the second quarter. Alps Advisors Inc. now owns 17,464 shares of the medical device company’s stock worth $579,000 after buying an additional 45 shares during the last quarter. Advisor Group Inc. raised its holdings in shares of Globus Medical by 2.0% in the second quarter. Advisor Group Inc. now owns 3,434 shares of the medical device company’s stock worth $114,000 after buying an additional 68 shares during the last quarter. Finally, 1st Global Advisors Inc. raised its holdings in shares of Globus Medical by 1.2% in the second quarter. 1st Global Advisors Inc. now owns 11,308 shares of the medical device company’s stock worth $375,000 after buying an additional 130 shares during the last quarter. 65.64% of the stock is owned by institutional investors and hedge funds.

About Globus Medical

Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.

Analyst Recommendations for Globus Medical (NYSE:GMED)

Receive News & Ratings for Globus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.